45 results about "Immature cells" patented technology

This invention provides an isolated electrophysiologically immature cell or its derivative that has been modified to provide a mature electrophysiological phenotype and populations of these cells. Compositions containing these cells and populations of cells are also provided by this invention. These cells and compositions have therapeutic and diagnostic uses. Non-limiting therapeutic uses include regenerating cardiac tissue, improving cardiac function, restoring action potential of cardiac tissue; and treating or preventing cardiac malfunction. The cells and population of cells also can be used diagnostically to screen drug or other therapeutic candidate.

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt / Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt / Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt / Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt / Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

Presented herein are methods of generating a multipotent or immature cell from a mature somatic cell, involving contacting a mature somatic cell with one or more small molecule compounds selected from: a histone deacetylase (HDAC) inhibitor; a glycogen synthase kinase 3 (GSK-3) inhibitor; one or more transforming growth factor-beta receptor (TGF-βR) inhibitors; one or more lysine-specific demethylase 1 (LSD1) inhibitors; a cAMP agonist; a histone lysine methyltransferase (EZH2) inhibitor; and a histone methyltransferase (HMTase) G9a inhibitor; valproic acid. Also provided are methods of generating a multipotent or immature cell from a somatic cell, by driving expression of OCT4, or an OCT4 functional homolog or derivative, under the control of a high expressing promoter. Presented herein are also methods of stem cell expansion, stem cell regeneration and differentiation, which comprise contacting stem cells with one or more small chemical compounds.

The invention relates to methods for altering and enhancing the immune response toward an antigen. More specifically, the present invention relates to methods of using CD40 engagement on T cells to induce T cell receptor gene rearrangement and enhance T cell affinity for a particular antigen. The invention also relates to methods for promoting developmental maturation of an immature cell of the T cell lineage.

The invention discloses a leukocyte classification and a classification method thereof, and the kit is composed of a water soluble quantum dots-cyanine dye probe, and an erythrocyte and platelet hemolytic agent, wherein the quantum dots-cyanine dye probe is composed of a stabilizing agent, which takes a polypeptides material as the quantum dots, and Cy5 cyanine dye covalent joint molecules whose emission spectrum is in the near infrared area, and has the characteristics of high quantum yield and sensitivity; the erythrocyte and platelet hemolytic agent can rapidly solves erythrocytes in the blood, and is composed of a cationic surfactant, a non-ionic surfactant, a pH buffer agent or combination of the cationic surfactant, the non-ionic surfactant, and the pH buffer agent. The leukocyte classification reagent provided by the invention can carry out precise subgroup identification on lymphocyte, monocyte, neutrophil, basophilic granulocyte, and acidophilic granulocyte in leukocytes of blood samples, and further identify immature cells or abnormal cells.

The invention discloses a modified enhanced type DC-CIK cell targeting immune cell mass, and a preparation method and application thereof. A method for preparing a DC cell comprises the following steps: performing isolated culture on monocyte, thereby acquiring an immature DC cell; and performing tumor antigen load and induced differentiation culture on the immature DC cell, thereby acquiring a mature DC cell, wherein the monocyte is acquired by separating from a peripheral blood mononuclear cell of a sample. The method for preparing CIK comprises the following steps: performing in vitro differentiation culture on a CIK cell, thereby acquiring an immature CIK cell; preparing a modifying recombined slow virus for performing in vitro modification on the CIK cell; and co-culturing the modified CIK cell and the DC cell, thereby acquiring the mature modified CIK cell (Triumph-DC-CIK), so as to be used for achieving a better tumor immunotherapy effect.

The invention discloses a DC cell and a targeting immune cell population, and a preparation method and application thereof. The preparation method of DC cells includes the steps of: conducting first induced differentiation culture on mononuclear cells in order to obtain immature DC cells; transfecting the immature DC cells by using HSV-2 antigen mRNA, so as to obtain transfected immature DC cells; and conducting second induced differentiation culture on the transfected immature DC cells, so as to obtain mature DC cells, wherein the mononuclear cells are isolated from mononuclear cells of peripheral blood of a sample. The method can prepare DC cells safely and efficiently, has a low cost and high efficiency, and can effectively solve the problem of cytotoxicity. The method can be effectively used for immune cell treatment or stimulation of lymphocytes derived from a same patient to produce a targeting cell population containing a large amount of CTL cells, and then the cell population can be used for virus infection immunotherapy to reach better effect.

The present invention provides methods and compositions of engineered cells for use in the continuous or transient delivery of growth factors and angiogenesis modulating agents, such as vascular endothelial growth factor (VEGF), in conjunction with constructs for replacing or augmenting organ functions. In one aspect of the invention, the genetically engineered cells can be immature cells that are capable of differentiating and assimilating into the target region. The methods of the present invention can be used to enhance vascularization locally at a target site in need of repair, growth, or implantation through the incorporation of autologous cells which have been genetically engineered to secrete a growth factor or angiogenesis modulating agent.

The invention discloses a DC cell based on SP17 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SP17 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

Provided are age-modified cells and method for making age modified cells by reducing or increasing the level of genomic nucleic acid methylation in the cells. The aging and / or maturation process can be accelerated or reduced and controlled for young, aged, mature and / or immature cells, such as a somatic cell, a stem cell, a stem cell-derived somatic cell, including an induced pluripotent stem cell-derived cell, by reducing or increasing the level of genomic nucleic acid methylation in the cells. Methods described by the present disclosure can produce age-appropriate cells from a somatic cell or a stem cell, such as an old cell, young cell, immature cell, and / or a mature cell. Such age-modified cells constitute model systems for the study of late-onset diseases and / or disorders.

The invention relates to a Chinese medicinal composition for treating chronic myeloid leukemia, which consists of the following components: 15 to 25 grams of rehmanniae praeparatum, 8 to 16 grams of tree peony bark, 18 to 28 grams of honey-fried extract glycyrrhiza, 18 to 32 grams of spreading hedyotis herb, 14 to 20 grams of lalang grass rhizome, 18 to 28 grams of glossy privet fruit, 14 to 28 grams of desertliving cistanche, 4 to 8 grams of cordyceps sinensis, 12 to 20 grams of Indian iphigenia bulb, 8 to 16 grams of stiff silkworm and 8 to 16 grams of eupolyphaga. The Chinese medicinal composition can carry out pertinence treatment on chronic myeloid leukemia, selectively inhibits and kills immature cells, induces apoptosis of leukemia cells, has strong pertinence and better treatment effect, promotes differentiation and maturation of leukemia cells, regulates qi and blood, strengthens the immunity, promotes recovery of the normal hematopoietic function of bone marrow, reduces reversion, prevents tolerance from being generated, reduces the toxic or side effects of chemotherapy and strengthens physical fitness.

The invention discloses a preparation method and application of modified enhanced DC-CIK targeting immune cell populations. A method for preparing DC cells includes subjecting monocyte to isolation culture to obtain immature DC cells, and subjecting the immature DC cells to tumor antigen loading and induction and differentiation culture so as to obtain mature DC cells, wherein the monocyte is obtained by separating single karyocyte of peripheral blood of samples. A method for preparing CIK includes subjecting CIK cells to in-vitro differentiation culture to obtain immature CIK cells, preparing recombinant lentivirus for modification to perform in-vitro modification on the CIK cells, and subjecting the modified CIK cells and the DC cells to co-culture so as to obtain mature modified CIK cells (Platinum-DC-CIK). The mature modified CIK cells (Platinum-DC-CIK) are used to improve tumor immunotherapy effect.

The invention relates to a technical process for synthesizing a camptothecin sugar derivative by artificially inducing nothapodytes nimmoniana (graham) mablerley endophyte. The process disclosed by the invention comprises the following steps of: charging immature cells of nothapodytes nimmoniana (graham) mablerley into an amplification culture medium according to the proportion of inoculation amount of 50-200g / L wet weight and culturing at 25-30 DEG C; adding 1-2,000 mummol / L of combined elicitor and 20-50g / L of sugar in the exponential growth initial period of the cells; adding a saccharified reagent and catalyst for carrying out saccharification reaction; and adding 1-2,000 mummol / L of combined elicitor for inducing in the exponential growth metaphase of the cells. The method disclosed by the invention realizes the synthesis of the camptothecin derivative in an artificial inducing way by utilizing the characteristics of the endophyte of the nothapodytes nimmoniana (graham) mablerley which is the camptothecin producing plant and cansolve the problems of lower conversion rate, high technical requirement on strain culture, more separating steps, and the like existing in the traditional biosynthesis methods and provide reference for the research of camptothecin as well as the anticancer effect and anticancer medicines thereof.

The invention discloses bovine colostrum formula powder for pregnant women. The powder contains bovine colostrum, folic acid, vitamin A and vitamin D. Wherein, folic acid can promote the maturation of immature cells in the marrow, so that macrocytic anemia and leucocytopenia that are caused by the lack of folic acid can be avoided. Vitamin A has the functions of maintaining the visual sense, promoting growth and development, keeping epithelial structure integral and sound, enhancing the immunity and removing free radicals. And vitamin D can increase the absorption of calcium and phosphor by human bodies so as to make the levels of plasma calcium and plasma phosphor reach the saturation degree; promote growth and skeleton calcification as well as healthy teeth; increase the absorption of phosphor through the intestinal wall, and the reabsorption of phosphor through kidney tubules; maintain the normal level of citrate in blood; prevent amino acid losing from the kidney, and pregnant women need to supplement lots of calcium during the gestation period, while vitamin D is conducive to calcium absorption.

The invention discloses a DC cell based on P53 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by P53 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a DC cell based on SPANXA1 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SPANXA1 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a DC cell based on BCG1 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by BCG1 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention provides a method for efficiently preparing DC1 cells through T cell culture medium supernatant. Peripheral blood of tumor patients or healthy people is processed, immature DC cells are separated out, and a product where DC1 cells are enriched is obtained through oriented induction. The product prepared in this way has the capacity for efficiently inducing tumor specific CTL cells and Th1 cells, and can be used for optimizing the clinical effect of the tumor immunity treatment technology. In addition, the invention further provides a method for using the prepared DC1 cells for preparing tumor antigen specific CTL cells. After the DC1 cells are loaded with tumor specific antigens, one part of the DC1 cells are conveyed back into patient bodies, the other part of the DC1 cells are used for in-vitro tumor antigen specific induction cytotoxic lymphocytes (CTL), and the specific immune reaction of tumors is activated through an in-vivo / in-vitro and active induction / passive induction combined mode.

The invention discloses a DC cell based on HBV1 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of the DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by HBV1 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, the DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a DC cell based on PSA antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by PSA antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention provides a traditional Chinese medicine composition for treating acute myeloblastic leukemia (AML) M1. The composition is prepared from the following components: 15-25g of radix rehmanniae, 8-16g of cortex moutan, 4-8g of honey-fried liquorice, 18-32g of oldenlandia diffusa, 14-20g of lalang grass rhizome, 18-28g of glossy privet fruit, 14-28g of herba cistanche, 4-8g of cordyceps sinensis, 15-25g of folium isatidis, 8-16g of wild radix ophiopogonis and 8-16g of honeysuckle. The medicine provided by the invention has the following functions: pertinently treating specific AML-M1, selectively inhibiting and killing immature cells, inducing leukemia cell apoptosis and having stronger pertinence and higher treatment effect; promoting differentiation and maturity of leukemia cells; regulating qi and blood and enhancing immunity; promoting recovery of normal hematopoietic function of marrows; and reducing reversion and preventing medicine resistance.

The invention discloses an antibody combination for replacing a lateral scattering light signal in mass spectrum flow type blood tumor immunotyping. The antibody combination comprises a Lactoferrin antibody and a Lysozyme antibody. The invention also discloses a portal method for mass spectrum flow type blood tumor immune typing. The invention further discloses a kit for mass spectrum flow type blood tumor immune typing. According to the invention, a Lactoferrin antibody and a Lysozyme antibody are adopted for the first time, a two-stage enclosure strategy is carried out in combination with a CD45 antibody, and a mass spectrometry flow cytometry is matched, so that the traditional flow CD45 / SSC can be replaced to distinguish mature granulocytes, mononuclear cells, nucleated red blood cells, lymphocytes, primitive and immature cells, abnormal cell subgroups and other subgroups in bone marrow; the technical problem that the SSC cannot be detected in the blood tumor cell analysis of a mass spectrum flow type is broken through, and the immunotyping depth of the current blood tumor can be improved by combining the multi-parameter high-throughput characteristic of the mass spectrum flow type.

The invention relates to a technical method for synthesizing 10-hydroxy camptothecin by artificially inducing icacinaceae endophyte. The method comprises the following steps of: filling immature cells of icacinaceae in an amplification culture medium according to a proportion of inoculum size to wet weight of between 50 and 200g / L and culturing at the temperature of between 25 and 30 DEG C; adding combined inducer at the concentration of between 1 and 2,000 mu mol / L and sugar at the concentration of between 20 and 50g / L at the cell index growth initial stage; and adding the combined inducer at the concentration of between 1 and 2,000 mu mol / L at the cell index growth medium stage for induction. In the method, the characteristics that the endophyte is easy to culture and control and fast in growth, and the like are utilized, the 10-hydroxy camptothecin which has the same physiological activity as a plant source can be produced in an artificial induction mode in combination with the characteristics of the icacinaceae which is used as a raw material for producing the camptothecin; the method has the advantages of low cost and easiness in industrial production; and a new approach can be developed for searching anti-cancer medicaments in view of microorganisms.

The invention discloses a traditional Chinese medicine combination for treating acute granulocyte AML-M4 leukemia, comprising the following compositions: 15-25g of root of rehmannia, 8-16g of tree peony bark, 4-8g of fired powder liquorice with honey, 18-32g of Ophiorrhiza pumila, 14-20g of rhizoma imperatae, 18-28g of ligustrum lucidum, 14-28g of herba cistanche, 4-8g of aweto, 12-24g of brown lily, 10-20g of radix patriniae heterophylla and 11-21g of smilax glabra. The medicament treats concrete AML-M4 acute granulocytic leukemia with pertinence, selectively inhibits and kills immature cells, induces apoptosis of leukemia cells, has stronger pertinence and higher curative effect and has the effects of promoting differentiation and maturation of the leukemia cells, regulating qi and blood, strengthening the immunologic function, promoting recovery of marrow normal hematopoietic function, reducing reversion, preventing production of drug resistance, reducing the toxic and side effects of chemotherapy and improving the physique.

The invention discloses a DC cell based on SURVIVIN antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by SURVIVIN antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a DC cell based on HPVE6 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by HPVE6 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, the DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a traditional Chinese medicine combination for treating acute granulocyte AML-M2 leukemia, comprising the following compositions: 15-25g of root of rehmannia, 8-16g of tree peony bark, 4-8g of fired powder liquorice with honey, 18-32g of Ophiorrhiza pumila, 14-20g of rhizoma imperatae, 18-28g of ligustrum lucidum, 14-28g of herba cistanche, 4-8g of aweto, 15-25g of Chinese yam, 10-20g of lanceolata and 10-20g of astragalus. The medicament treats concrete AML-M2 acute granulocytic leukemia with pertinence, selectively inhibits and kills immature cells, induces apoptosis of leukemia cells, has stronger pertinence and higher curative effect and has the effects of promoting differentiation and maturation of the leukemia cells, regulating qi and blood, strengthening the immunologic function, promoting recovery of marrow normal hematopoietic function, reducing reversion, preventing production of drug resistance, reducing the toxic and side effects of chemotherapy and improving the physique.

The invention discloses a DC cell based on HM1.24 antigen, a targeting immune cell population, a preparation method and applications thereof. The preparation method of DC cell comprises the following steps: subjecting mononuclear cells to first induced differentiation culture to obtain immature DC cells; transfecting the immature DC cells by HM1.24 antigen mRNA to obtain transfected immature DC cells; subjecting the transfected immature DC cell to second induced differentiation culture to obtain mature DC cells; wherein the mononuclear cells are separated from peripheral blood mononuclear cells of a sample. Through the provided preparation method, DC cells can be obtained efficiently and safely. Moreover, the provided preparation method has the advantages of low cost and high efficiency, and can effectively solve the problem of cell toxicity. The DC cells can be applied to cell immunotherapy or used to trigger the lymph cells from the same patient to generate targeting immune cell population rich in CTL cells so as to achieve a better effect in tumor immunotherapy.

The invention discloses a DC cell and a targeting immune cell population, and a preparation method and application thereof. The preparation method of DC cells includes the steps of: conducting first induced differentiation culture on mononuclear cells in order to obtain immature DC cells; transfecting the immature DC cells by using BA46 antigen mRNA, so as to obtain transfected immature DC cells; and conducting second induced differentiation culture on the transfected immature DC cells, so as to obtain mature DC cells, wherein the mononuclear cells are isolated from mononuclear cells of peripheral blood of a sample. The method can prepare DC cells safely and efficiently, has a low cost and high efficiency, and can effectively solve the problem of cytotoxicity. The method can be effectively used for immune cell treatment or stimulation of lymphocytes derived from a same patient to produce a targeting cell population containing a large amount of CTL cells, and then the cell population can be used for tumor immunotherapy to reach better effect.